🔗 Permalink

Inventor profile of:

Gregory L. Moore

City:

Monrovia, California

Country:

United States

Published Applications:

Last publication date:

2026-06-11

Top Assignees for applications by Gregory L. Moore

The entities that hold a legal rights for patent applications filed by inventor Moore Gregory L.:

XENCOR, INC. 32 Monrovia, CA United States
Xencor, Inc. 3 Pasadena, CA United States

Recent patent applications by Moore Gregory L.

Gregory L. Moore from Monrovia, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-06-11

US20260159590A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#2 | 2026-06-04

US20260152576A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#3 | 2026-03-26

US20260085132A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#4 | 2026-02-05

US20260035485A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#5 | 2026-01-29

US20260028429A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#6 | 2025-07-17

US20250230262A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#7 | 2025-04-10

US20250114440A1

Human necessities

Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

#8 | 2023-07-20

US20230227560A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES

#9 | 2021-12-23

US20210395363A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#10 | 2021-09-16

US20210284754A1

Chemistry; metallurgy

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#11 | 2021-07-08

US20210205426A1

Human necessities

Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

#12 | 2021-01-14

US20210009690A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#13 | 2021-01-14

US20210009689A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#14 | 2020-03-05

US20200071402A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#15 | 2019-10-31

US20190330342A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#16 | 2019-10-17

US20190315861A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#17 | 2018-08-02

US20180215822A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#18 | 2018-08-02

US20180215821A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#19 | 2017-08-31

US20170247470A9

Chemistry; metallurgy

RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES

#20 | 2016-05-05

US20160122435A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

#21 | 2016-03-10

US20160068588A1

Chemistry; metallurgy

ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERING

#22 | 2016-03-03

US20160060360A1

Chemistry; metallurgy

RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES

#23 | 2015-02-05

US20150037322A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#24 | 2015-02-05

US20150037321A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32b expressing cells

#25 | 2014-12-18

US20140370013A1

Chemistry; metallurgy

Heterodimeric proteins

#26 | 2014-10-02

US20140294833A1

Chemistry; metallurgy

Heterodimeric proteins

#27 | 2014-07-31

US20140212436A1

Chemistry; metallurgy

Rapid clearance of antigen complexes using novel antibodies

#28 | 2014-07-31

US20140212435A1

Chemistry; metallurgy

RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES

#29 | 2013-11-28

US20130315910A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#30 | 2013-07-04

US20130171095A1

Chemistry; metallurgy

Heterodimeric human IgG1 polypeptides with isoelectric point modifications

#31 | 2013-05-16

US20130122001A1

Chemistry; metallurgy

Antibody variants with enhanced complement activity

#32 | 2012-12-20

US20120321620A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#33 | 2012-06-21

US20120156220A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#34 | 2012-06-21

US20120156207A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#35 | 2012-06-14

US20120148578A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32b expressing cells

#36 | 2011-09-29

US20110236375A1

Chemistry; metallurgy

Antibody variants with enhanced complement activity

#37 | 2011-08-04

US20110189178A1

Human necessities

Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

#38 | 2011-03-03

US20110054151A1

Chemistry; metallurgy

Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens

#39 | 2009-05-28

US20090136485A1

Chemistry; metallurgy

Methods and compositions for inhibiting CD32B expressing cells

#40 | 2009-02-12

US20090042291A1

Chemistry; metallurgy

Optimized Fc variants

#41 | 2007-03-08

US20070054359A1

Chemistry; metallurgy

Rational Chemical Modification of Adiponectin Variants

#42 | 2007-01-11

US20070010659A1

Human necessities

Adiponectin variants

#43 | 2006-12-14

US20060281151A1

Chemistry; metallurgy

Globular adiponectin variants

#44 | 2006-12-07

US20060276395A1

Human necessities

Pharmaceutical compositions of adiponectin variants and methods of storage

#45 | 2006-11-30

US20060270598A1

Human necessities

Method of treatment using adiponectin variants

InventorID:

246580 ⎘